AML#
|
Cytogenetics
|
FLT3 Status
|
NPM1 Status
|
CD33 MFI
|
Pgp status
|
Tip%cell loss1
|
GO%cell loss1
|
Tip/GO%cell loss1
|
Δtox2
|
---|
#19
|
normal
|
WT
|
WT
|
1.7
|
NEG
|
33
|
70
|
85
|
-
|
#1
|
normal
|
ITD
|
MUT
|
74
|
NEG
|
60
|
23
|
82
|
−1
|
#10
|
plus 8
|
ITD
|
WT
|
3.7
|
NEG
|
54
|
3
|
75
|
18
|
#17
|
inv(16)
|
ITD
|
WT
|
22
|
NEG
|
35
|
27
|
75
|
13
|
#13
|
normal
|
WT
|
WT
| |
NEG
|
42
|
39
|
74
|
−7
|
#3
|
inv(16)
|
WT
|
WT
|
19
|
POS
|
36
|
0
|
70
|
34
|
#15
|
—
|
ITD
|
WT
|
3.3
|
POS
|
50
|
17
|
69
|
2
|
#27
|
complex
|
ITD
|
WT
|
38
|
NEG
|
0
|
0
|
68
|
68
|
#33
|
del(13)
|
ITD
|
—
|
198
|
NEG
|
38
|
19
|
65
|
8
|
#14
|
normal
|
ITD
|
MUT
|
8.7
|
NEG
|
43
|
4
|
65
|
18
|
#32
|
—
|
ITD
|
MUT
|
46
|
NEG
|
19
|
18
|
65
|
28
|
#8
|
normal
|
WT
|
MUT
|
83
|
NEG
|
20
|
12
|
63
|
31
|
#12
|
inv(16)
|
WT
|
WT
|
1.5
|
NEG
|
56
|
28
|
63
|
−21
|
#26
|
—
|
ITD
|
MUT
| |
NEG
|
22
|
31
|
58
|
5
|
#11
|
—
|
ITD
|
MUT
|
43
|
NEG
|
11
|
1
|
55
|
43
|
#30
|
—
|
WT
|
WT
|
38
|
NEG
|
29
|
18
|
54
|
7
|
#34
|
normal
|
ITD
|
MUT
|
1.3
|
NEG
|
4
|
42
|
52
|
6
|
#20
|
—
|
WT
|
WT
|
30
|
POS
|
27
|
23
|
50
|
0
|
#21
|
del(5q)
|
ITD
|
MUT
|
59
|
NEG
|
40
|
25
|
49
|
−16
|
#5
|
normal
|
ITD
|
MUT
|
75
|
NEG
|
0
|
16
|
46
|
30
|
#25
|
dup1, add12, add16
|
WT
|
—
|
36
|
POS
|
18
|
10
|
43
|
15
|
#9
|
normal
|
ITD
|
MUT
|
8.4
|
NEG
|
19
|
19
|
42
|
4
|
#6
|
normal
|
ITD
|
MUT
|
0.19
|
NEG
|
31
|
37
|
41
|
−27
|
#16
|
—
|
—
|
—
|
51
|
—
|
21
|
21
|
40
|
−2
|
#4
|
—
|
ITD
|
MUT
|
89
|
NEG
|
33
|
0
|
35
|
2
|
#35
|
complex
|
WT
|
WT
|
18.2
|
POS
|
14
|
5
|
21
|
2
|
#31
|
normal
|
ITD
|
WT
|
11
|
POS
|
7
|
0
|
20
|
13
|
#2
|
—
|
WT
|
WT
|
3.4
|
POS
|
2
|
0
|
17
|
15
|
#7
|
plus 11
|
WT
|
WT
|
23
|
NEG
|
0
|
3
|
15
|
12
|
#29
|
normal
|
WT
|
MUT
|
140
|
NEG
|
16
|
0
|
14
|
−2
|
#28
|
complex
|
—
|
—
|
4.9
|
POS
|
0
|
2
|
2
|
0
|
#18
|
−5
|
WT
|
WT
|
2.1
|
POS
|
0
|
8
|
0
|
−8
|
#36
|
—
|
WT
|
WT
|
6.3
|
—
|
9
|
2
|
0
|
−11
|
#23
|
—
|
WT
|
WT
|
36
|
—
|
0
|
1
|
0
|
−1
|
- 34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).
-
1% of cells lost after 48 hours treatment (compared to untreated control).
-
2 Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.